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Abstract
Introduction Late cardiotoxicity is a known complication
of anthracycline therapy but the long-term effects of low
cumulative doses are not well documented. We studied late
cardiotoxicity in survivors of childhood acute lymphoblastic
leukemia (ALL) treated with low anthracycline doses 10 to
20 years earlier.
Methods Seventy-seven ALL survivors who received a
cumulative anthracycline dose <250 mg/m² and were at
least 10 years after treatment were evaluated for signs of
clinical heart failure. Cardiac function was assessed by
echocardiography including tissue Doppler measurements
of the septal mitral annulus in 37 ALL survivors 10.6–
18.3 years (median 13.3 years) after anthracycline treatment
with cumulative doses of 180 (n=19) or 240 mg/m² (n=18).
The control group consisted of 30 healthy volunteers
matched for age, sex, BSA, and BMI.
Results No clinical relevant cardiotoxicity was found. Left
ventricular shortening fraction (SF) was significantly
reduced in male ALL survivors. Three of the 19 male
ALL survivors had an SF below 30%. Male ALL survivors
showed a significantly lower early filling velocity to atrial
contraction velocity ratio but myocardial velocity during
early filling was comparable between patients and controls.
ALL survivors had a significantly longer isovolumetric
relaxation time (IVRT). Thirty percent of the ALL
survivors have an abnormal IVRT compared to the normal
range of the controls.
Conclusion and implications for cancer survivors At a
median of 13.3 years after exposure to cumulative doses of
anthracyclines of 180 or 240 mg/m², no clinical relevant
cardiotoxicitywasfoundbutsubclinicalcardiac abnormalities
were present in 30% of the patients.
Keywords Cardiotoxicity after cancer therapy.ALL.Late
effects.Anthracycline-related cardiotoxicity
Introduction
Anthracycline antibiotics, predominantly doxorubicin
(DOX) and daunorubicin (DNR), are highly effective in
the treatment of childhood malignancies, but are potentially
cardiotoxic at all dose ranges. Studies from the early 1990s
showed a high incidence of late myocardial damage in
previously well long-term survivors of childhood cancer
[1–3]. As many as 65% of acute lymphoblastic leukemia
(ALL) survivors showed subclinical abnormalities of left
ventricular (LV) systolic function at a mean of 6.4 years
after the completion of anthracycline therapy with a
cumulative dose of 228 to 550 mg/m² [2]. More recent
reports have shown that the prevalence of cardiac abnor-
malities is much lower with cumulative anthracycline doses
of less than 250–300 mg/m² [4, 5]. No late cardiac damage
was demonstrated in childhood ALL survivors at a median
of 14.8 years after induction treatment including a
cumulative dose of DNR 100 mg/m², compared to
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DNR[6]. Most reports of late anthracycline cardiotoxicity
concern studies of heterogeneous diagnostic groups receiving
various anthracycline cumulative doses and having a mean
duration of follow-up after anthracycline exposure of less
than 10 years.
Serial monitoring of left ventricular function by means
of echocardiography (through measurement of the shortening
fraction (SF)) has been advocated but LV restriction is a late
functional event and SF is also influenced by the loading
conditions of the heart. In some previous studies, different
indicators of subclinical damage as elevation of afterload
(end-systolic stress) [2, 4, 7] and impaired relaxation [7, 8]
have been documented, with SF being normal.
Tissue Doppler imaging (TDI) has shown to be very
sensitive in identifying subclinical cardiomyopathy in
various conditions [9, 10].
We report the results of a cardiac evaluation with the use
of tissue Doppler imaging of the septal mitral annulus
besides standard 2D- and M-mode echocardiography in
long-term survivors of childhood ALL at a mean of
13.6 years after anthracycline treatment with a cumulative
dose of 180 or 240 mg/m².
Study population and methods
Study population
The subjects of the study were long-term survivors of ALL in
first complete remission who received a cumulative anthracy-
cline dose <250 mg/m² and were at least 10 years after
treatment. Patients with Down syndrome or a congenital heart
disease were excluded. Eighty-five survivors meeting these
criteria were identified from our center-based registry. Seventy-
seven of them are still attending our long-term follow-up clinic
and none of them has signs of clinical heart failure. Thirty-
seven patients agreed to participate in the study. All patients
were treated in our center according to the EORTC-ALL-
58831/2 (33 patients) or 58881-protocol (four patients). They
received DNR 120 mg/m2 as part of the induction treatment
andDOX60or120mg/m²aspartofthere-inductiontreatment.
The cumulative dose of cyclophosphamide was 0 or 2 g/m² in
the low-risk group and 3 g/m² in the medium and high risk
group. No patient received radiotherapy of the mediastinum.
The patients in the low-risk group did not receive prophylactic
cranial irradiation, the patients in the medium and high-risk
group without CNS involvement at diagnosis were randomized
to receive prophylactic cranial irradiation or not. More details
about the risk group definition and treatment are found in the
article by Vilmer et al. [11].
The control group consisted of 31 healthy volunteers
matched for age, sex, and BSA since 11 out of the 37
patients were still in puberty and echocardiographic
parameters are increasing with somatic growth (chamber
size and wall thickness). They were also matched for BMI
because of the potential influence of body composition on
cardiac function. These 31 control subjects were chosen out
of a larger group of healthy children, adolescents, and
young adults who volunteered to undergo the same cardiac
evaluation.
The study protocol was approved by the hospital ethical
review board.
Methods
The cardiac evaluation consisted of an interview with
attention for cardiac-related problems, measurement of
blood pressure, a 12-lead electrocardiogram (ECG) and a
complete echocardiographic study with a simultaneous
ECG (standard lead II).
Echocardiographic study
A complete echocardiographic study with a simultaneous
ECG (standard lead II) was performed on each patient and
control subject by a single observer to avoid interobserver
variability. Guided by two-dimensional echocardiography,
standard M-mode recordings of the left ventricular dimensions
and function were obtained. Left ventricular posterior wall
thickness at end systole (LVPWS) and at end diastole
(LVPWD) and left ventricular internal dimensions at end
systole (LVIDS) and at end diastole (LVIDD) were measured.
SF was calculated according to the formula (LVIDD−LVIDS/
LVIDD)×100%. A SF of <28% was considered as abnormal.
End-systolic wall stress (ESWS) was calculated according to
the Rowland formula [12]. The left ventricular mass index and
relative posterior wall thickness were calculated according to
the formula of Devereux et al. [13]. Conventional Doppler
tracings of the mitral and the tricuspid valve and pulmonary
venous return flow were obtained from an apical four-
chamber view; the Doppler cursor line was placed in the inlet
at an angle as parallel to flow as possible and in the position of
m a x i m a lv e l o c i t yt om e a s u r ep e a ke a r l y( E) and peak atrial (A)
velocities. E/A ratio, being an indicator of diastolic function,
was calculated. Isovolumetric relaxation time (IVRT) was
measured as the time interval between the first high-frequency
component of the second heart sound (on the phonocardio-
gram) and the onset of early ventricular filling. Doppler
values of the aortic and pulmonary flow were measured from
the suprasternal and parasternal short axis respectively.
Duration values were corrected for heart rate. Tissue Doppler
values of the septal mitral annulus were obtained from the
apical four-chamber view, peak early diastolic (E′), atrial (A′),
and systolic (S) velocities were measured. The E/E′ratio of
early mitral flow velocity (E) to early diastolic velocity of the
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of combined systolic and diastolic myocardial performance
(Tei index or myocardial performance index according to Tei
(MPI)), defined as the sum of IVRT and isovolumetric
contraction time (ICT) divided by ejection time (ET), was used
forquantificationofthegloballeftventricularfunction[14]. All
Doppler signals were recorded at a speed of 50 mm/s.
For each parameter, the average of 3 cycles was used.
Statistical analysis
Values are given as median, minimal, and maximal value in
parentheses. Differences between the patient and control
group were evaluated using Mann–Whitney U test. Two-
sided P values ≤0.05 are considered significant. Potential
associations of cumulative dose, gender, age at diagnosis,
and duration of follow-up were explored using univariate
and multiple regression techniques. Calculations were
performed with the Statistical Package for Social Science
version 12 and 15 statistical software program.
If no normal range has been defined in the literature for a
given variable in this age group, a value of a given variable
in the patient group was considered as abnormal if >[Q3+
1.5(Q3−Q1)] or <[Q1−1.5(Q3−Q1)] of this variable in the
control group, conform the definition of an outlier in the
box-and-whisker plot used to illustrate the comparison of a
continuous variable between two independent groups.
Results
Patient characteristics
Characteristics of the complete cohort and the study
patients are summarized in Table 1. The study patients
reflect the complete cohort concerning sex distribution, age
at diagnosis, age at time of study, duration of follow-up
since completion of anthracycline treatment and anthracy-
cline dose. Thirty seven adolescents and young adults, 19
males and 18 females, were examined. The median age at
the time of diagnosis of the leukemia and onset of treatment
was 4.8 years (range 0.2–12.2 years). The median age at the
time of the study was 19 years (range 11.6–26.8 years). The
patients were examined at a median of 13.3 years (range
10.6–18.3 years) after completion of the anthracycline
treatment. Nineteen patients received a cumulative anthra-
cycline dose of 180 mg/m² and 18 of 240 mg/m². Nine
patients received prophylactic cranial irradiation, one
patient developed growth hormone deficiency, no patient
received growth hormone treatment.
Clinical evaluation
None of the patients had cardiopulmonary symptoms at
the time of assessment, so all were in NYHA I. The
patients and controls were comparable with respect to age,
sex, body surface area, body mass index, and systolic blood
pressure. Male patients had a significantly and female
patients a nearly significantly higher diastolic blood pressure
(Table 2).
Twelve-lead ECG
No patients showed ECG abnormalities, the QTc interval
was <0.44 s in all patients.
Left ventricular dimensions and systolic function
Left ventricular wall dimensions and end-systolic wall
stress were comparable between patients and controls but
the LVPW thickening was significantly reduced in male
patients (Table 3).
The shortening fraction and the ejection fraction were
significantly lower in the male patient group but not in
Complete cohort Study patients P value
a
Patients, N 85 37
Female sex, N (%) 43 (50.6) 16 (43.2) NS
Age at diagnosis <4 years, N (%) 35 (41.2) 15 (40.5) NS
Age at diagnosis (years)
Median (range) 4.8 (0.2–13.7) 4.8 (0.2–12.2) NS
Age at time of study (years)
Median (range) 19.8 (11.6–28.4) 19.0 (11.6–26.8) NS
Years since anthracycline treatment
Median (range) 13.9 (10.6–18.8) 13.3 (10.6–18.3) NS
Anthracycline dose
180 mg/m
2, N (%) 51 (60) 19 (51.4) NS
240 mg/m
2, N (%) 34 (40) 18 (48.6) NS
Table 1 Characteristics of
complete cohort and study
patients
NS non significant
aTesttype:nonparametrictest,two
independent samples (Mann–
Whitney U)
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if <28%, none of the patients has an abnormal value but if
defined as abnormal if <30%, three of the 37 patients (8.1%)
have an abnormal value. If the EF is defined as abnormal
if <55%, the two male patients with a SF between 28%
and 29% have an abnormal value (54.6% and 54.7%).
The reduction in LV shortening in male ALL survivors
was accounted for by an increase in LVESWS (Pearson
correlation coefficient −0.59 with p>0.001 and Spearman
correlation coefficient −0.6 with p>0.001). The reduction
in LV shortening was also related to the reduced LVPW
thickening (Pearson correlation coefficient +0.37 with
Table 2 Clinical characteristics of patients and controls
Males Females
Patients Controls P value Patients Controls P value
N=19 N=16 N=18 N=14
Age (years) 18.8 (11.6–22.6) 17.4 (12.9–25.5) 0.297 19.8 (15.6–26.8) 17.5 (14.9–30.0) 0.382
BSA (m²) 1.84 (1.53–2.28) 1.81 (1.37–2.07) 0.947 1.66 (1.47–1.97) 1.65 (1.47–1.87) 0.482
BMI (kg/m²) 20.7 (18.6–30.7) 20.5 (17.0–25.3) 0.716 20.8 (16.5–27.4) 20.4 (16.5–29.4) 0.425
Systolic blood pressure (mmHg) 124 (104–140) 128 (106–146) 0.258 113 (100–131) 123 (98–137) 0.107
Diastolic blood pressure (mmHg) 70 (45–79) 58 (51–72) 0.001 70 (50–84) 60 (51–78) 0.058
Values are expressed as median (range); significant P values <0.05 in bold
Table 3 Comparison of left ventricular dimension, systolic function, diastolic function, and time intervals between patients and controls
Males Females
Patients Controls P value Patients Controls P value
Left ventricular dimensions
LVIDD (cm) 5.28 (4.76–6.22) 5.32 (4.68–6.04) 0.843 4.72 (4.26–5.19) 4.82 (3.80–5.76) 0.802
LVIDS (cm) 3.46 (3.03–4.13) 3.42 (2.91–3.78) 0.260 3.08 (2.60–3.31) 3.06 (2.38–3.51) 0.706
LVPWD (cm) 0.66 (0.51–0.82) 0.57 (0.50–0.74) 0.064 0.58 (0.47–0.75) 0.53 (0.40–0.72) 0.062
LVPWS (cm) 1.15 (0.92–1.46) 1.18 (1.00–1.34) 0.842 1.13 (0.87–1.35) 1.12 (0.86–1.34) 0.785
LVPWth (%) 45.8 (27.2–52.4) 48.7 (37.6–59.0) 0.016 50.0 (38.5–57.1) 52.1 (39.5–61.2) 0.075
LVESWS (g/cm²) 98.5 (69.5–118.7) 86.7 (69.2–125.5) 0.640 78.1 (54.7–107.9) 85.1 (56.9–110.4) 0.405
LVmass (g) 132 (87–184) 121 (93–188) 0.196 95 (67–144) 85 (60–152) 0.217
LVmass Index (g/m²) 71 (56–105) 66 (53–91) 0.233 56 (43–73) 52 (36–81) 0.267
Systolic function
SF (%) 34.0 (28.6–39.4) 36.8 (31.6–40.1) 0.009 36.9 (30.4–40.8) 37.6 (31.1–44.4) 0.706
EF (%) 61.3 (54.6–70.5) 66.1 (59.2–70.3) 0.014 66.6 (58.6–71.6) 67.2 (58.8–76.1) 0.738
Diastolic function mitral valve and tissue Doppler imaging
E maximum (m/s) 0.78 (0.64–0.96) 0.78 (0.59–1.11) 0.817 0.85 (0.48–1.01) 0.88 (0.61–1.03) 0.210
A maximum (m/s) 0.46 (0.30–0.63) 0.36 (0.24–0.49) 0.002 0.46 (0.31–0.67) 0.45 (0.28–0.77) 0.403
E/A maximum 1.83 (1.34–2.66) 2.02 (1.66–3.27) 0.003 1.69 (0.74–2.89) 2.07 (1.27–3.11) 0.160
E′ (cm/s) 13.8 (9.4–17.3) 15.0 (10.1–18.8) 0.262 14.1 (9.9–19.3) 13.6 (12.0–15.4) 0.857
E/E′ 5.71 (4.65–7.53) 5.44 (3.61–7.99) 0.270 5.74 (4.47–8.25) 6.61 (4.00–8.50) 0.060
A′ (cm/s) 7.5 (5.1–9.7) 7.4 (4.0–11.5) 0.678 8.1 (3.9–11.5) 7.4 (5.7–10.0) 0.706
S (cm/s) 8.8 (7.5–11.0) 9.5 (6.7–12.9) 0.156 9.4 (8.1–15.2) 8.6 (7.4–10.2) 0.081
Time intervals
Tei index left ventricle 0.55 (0.42–0.68) 0.44 (0.38–0.49) <0.001 0.54 (0.40–0.81) 0.43 (0.38–0.52) 0.002
IVRT (ms) 75 (55–98) 63 (53–75) <0.001 80 (53–95) 60 (45–82) 0.003
ICT (ms) 83 (55–115) 60 (42–68) 0.001 70 (55–143) 62 (33–81) 0.053
ET (ms) 288 (245–332) 283 (252–310) 0.398 281 (227–340) 276 (262–300) 0.544
Values are expressed as median (range); significant P values <0.05 in bold
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p=0.030).
Diastolic function
Conventional Doppler measurements
The mitral (V maximum) A-wave velocity was significantly
higher in the male patient group with consequently
significantly lower early filling velocity to atrial contraction
velocity (E/A) ratio. This could not be demonstrated in the
female patient group. In none of the male patients the E/A
ratio was abnormal compared to the normal range in the
male controls (Table 3).
Tissue Doppler
Tissue Doppler-derived values of the septal mitral annulus
were comparable between patients and controls (Table 3).
Time intervals and duration
The Tei index for the left ventricle was significantly higher
in both male and female patient group due to a significantly
longer IVRT and a longer ICT which was significantly
longer in males and nearly significantly longer in females.
Ten of the 19 male and Two of the 16 female patients have
an abnormal Tei index compared to the normal range in the
controls. Eight of the 19 male and three of the 16 female
patients have an abnormal IVRT compared to the normal
range of the controls (Table 3).
Correlation analysis
We could not find any correlation between cumulative
anthracycline dose, age at diagnosis, and duration of
follow-up and the different cardiac parameters in the
patient group. Echocardiographic abnormalities were
found more frequently in the male ALL survivors but
the figures for the sex difference did not reach statistical
significance.
Discussion
In this study no clinical relevant late cardiac damage was
demonstrated in long-term survivors of childhood ALL
who received 180 or 240 mg/m² of anthracyclines 13.3 years
earlier. Subclinical cardiac abnormalities were present with
a prevalence varying depending on the parameters used to
address this topic.
Anthracyclines impair the growth potential of the
myocardium. Myocardial histology suggests that surviving
myocytes compensate to maintain normal cardiac structure
by hypertrophy.
Non-adequate myocyte growth in the years after treatment
finally causes a thinning of the wall of the left ventricle,
development of inappropriate afterload with in some cases
chamber dilatation and the development of cardiomyopathy.
Impairment of myocyte growth of the left ventricular
myocardium can be seen on echocardiography as a thinner
left ventricular wall with reduced left ventricular wall
thickness and mass [2, 4, 15, 16]. We did not find reduced
left ventricular dimensions or mass which can be explained
by the lower doses of anthracyclines our patients received.
The cumulative dose of anthracyclines is the most important
factor for cardiotoxicity in the previous studies. Although a
cumulative dose <250 mg/m² is said to be reasonably safe, it
has also been shown that no dose is completely safe [4, 5,
16, 17]. LV shortening, as determined by SF, was reduced in
male ALL survivors as compared to the healthy controls but
was still in the normal range with a SF <28% considered as
abnormal. If the SF is defined as abnormal if <30%, three of
the 37 patients (8%) have an abnormal value. Like others,
we documented that when the SF was abnormal, this was
accounted for by a reduced LVPW thickening and an
increase in LVESWS.
Diastolic changes have been found to precede systolic
dysfunction. Impaired relaxation has been proposed as a
consequence of chronic progressive myocardial damage
induced by anthracyclines [7, 8]. In this study, LV diastolic
performance was assessed from pulsed wave mitral Doppler
flow and tissue Doppler imaging. In the male ALL
survivors, the mitral (Vmaximum) A-wave velocity was
significantly higher with consequently significantly lower
early filling velocity to atrial contraction velocity (E/A)
ratio but in none of the patients the E/A ratio was abnormal
compared to the normal range of the controls. Early filling
velocity was comparable between patients' end controls.
Since mitral flow velocities are dependent on load present
during filling, LV diastolic performance was also assessed
from tissue Doppler imaging by measuring E′ as a parameter
of diastolic function independent of left ventricular filling.
Although E′ was lower in the male patients as compared to
the male controls, this difference did not reach statistical
significance. In general, E′ was comparable between patients
and controls as was E/E′. So we did not find clearly
abnormal left ventricular filling abnormalities with conven-
tional nor tissue Doppler imaging at the septal mitral
annulus. The applicability of TDI for estimating subclinical
myocardial dysfunction was more extensively studied by
other investigators [10, 18–20]. In contrast to our findings,
they could demonstrate an added value of TDI in detecting
signs of mostly subtle regional diastolic and systolic
myocardial dysfunction in asymptomatic patients after
exposure to low to moderate doses of anthracyclines.
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terized by significant lengthening of the isovolumetric
relaxation time. In 30% of the patients, the IVRT was
abnormal compared to the normal range of the controls.
IVRT is not only function of the rate of isovolumic
relaxation but also of the pressure gradient between the
pressure in the aorta just preceding closure of the aortic
valve and the pressure in the atrium upon opening of the
mitral valve. The possible influence of an altered pressure
gradient was assessed by measuring systolic blood pressure
and aortic pulse wave velocity which are related to left
ventricular afterload and which were comparable between
patient and control group. This was also the case for the
normalized pulmonary acceleration time which reflects
pulmonary arterial pressure and, indirectly, left atrial
pressure. Isovolumic relaxation is an active process
vulnerable to anthracycline toxicity. We suggest isovolumic
relaxation to be impaired due to reduced left ventricular
compliance being the first sign of systolic dysfunction.
Global left ventricular function was assessed by using
the Tei index or MPI. The Tei index was significantly
increased in the patient group. In comparison with the
normal range of the control group, 32% of the patients
have an abnormal Tei index. This is due to a significantly
longer IVRTand a nearly significantly longer ICT. The Tei
index has been described as a sensitive parameter for
detection ofsubclinical myocardialdysfunction.Several other
authors found an increased MPI as indicator of subclinical
damage in childhood cancer survivors after treatment with a
low to median dose of anthracyclines [17, 20, 21], and in two
of these studies, also due to a significantly prolonged IVRT
[17, 20].
We could not demonstrate a correlation with anthracycline
dose probably because both doses are low doses. We did not
find female gender or a young age at treatment, especially
youngerthan4years,tobeariskfactor.Wesuggestthatthisis
related to the fact that the previously found correlation is
weaker in the low cumulative anthracycline dose range. This
can be deduced from the curves about the probability of late
depressed fractional shortening in relation to cumulative
anthracycline dose and age at the time of diagnosis and about
the probability of late depressed contractility in relation to
cumulative anthracycline dose and sex provided by Lipshultz
et al.[22]. On the contrary, we found echocardiographic
abnormalities more frequently in male ALL survivors
although the figures for the sex difference did not reach
statistical significance. We do not think male ALL survivors
to be more prone to develop late anthracycline cardiotoxicity.
This is a finding from a small cohort that needs further study.
We could not demonstrate a correlation with longer
duration of follow-up. It is known that the risk of cardiac
abnormalities increases with time since anthracycline expo-
sure for patients who received a cumulative dose >250 mg/m²
[16, 23, 24] but this is not yet known for patients who
received a lower cumulative dose.
The small cohort of survivors is the main limitation of
our study. This causes less power in the statistical analysis.
The findings need further study to verify in a large cohort.
On the other hand data concerning the cardiovascular
status of survivors more than 10–15 years after completion
of treatment with cumulative doses in the range of 180–
240 mg/m² are still limited. These data are important
since the majority of the long-term survivors of childhood
cancer exposed to anthracyclines, received a cumulative
dose <250 mg/m².
In conclusion, at a median of 13.3 years after exposure
to a cumulative dose of anthracyclines of 180 or 240 mg/m²,
no clinical relevant cardiotoxicity was found but subclinical
cardiac abnormalities were present in up to one third of the
patients. Three of the 37 patients (8%) have an SF <30% and
11 of the 37 patients (30%) have a prolonged IVRTcompared
to the normal range of the controls. The prognostic signifi-
cance of the changes in these cardiac parameters is still not
well-known. Considering the growing knowledge of the
mechanisms of cardiotoxicity which can continue long after
the end of treatment [25, 26] and the lack of data of follow-
up on the very long-term, continuous follow-up of these
survivors is needed. Guidelines concerning cardiac monitor-
ing were recently developed by the cardiovascular disease
task force of the Children's Oncology Group [27]. Also after
exposure to a low dose of antracyclines, survivors should be
encouraged to follow a preventive heart healthy lifestyle and
monitored lifelong.
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